All Stories

  1. Metabolite profiling in early clinical drug development: current status and future prospects

    Article • Expert Opinion on Drug Metabolism & Toxicology, July 2017, Taylor & Francis

    Dr Jasper Dingemanse

  2. Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment

    Article • The Journal of Clinical Pharmacology, June 2017, Wiley

    Dr Jasper Dingemanse

  3. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension

    Article • Expert Opinion on Drug Safety, May 2017, Taylor & Francis

    Dr Jasper Dingemanse

  4. Pharmacokinetics of Macitentan in Patients With Pulmonary Arterial Hypertension and Comparison With Healthy Subjects

    Article • The Journal of Clinical Pharmacology, April 2017, Wiley

    Dr Jasper Dingemanse

  5. Effects of multiple-dose ponesimod, a selective S1P1 receptor modulator, on lymphocyte subsets in healthy humans

    Article • Drug Design Development and Therapy, December 2016, Dove Medical Press

    Dr Jasper Dingemanse

  6. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949

    Article • British Journal of Clinical Pharmacology, November 2016, Wiley

    Dr Jasper Dingemanse

  7. Three different up-titration regimens of ponesimod, an S1P1receptor modulator, in healthy subjects

    Article • The Journal of Clinical Pharmacology, February 2015, Wiley

    Dr Jasper Dingemanse

  8. A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist

    Article • Drug Design Development and Therapy, December 2014, Taylor & Francis

    Dr Jasper Dingemanse, Dr Meijian Zhou

  9. First-in-Humans Study of the Safety, Tolerability, and Pharmacokinetics of ACT-451840, a New Chemical Entity with Antimalarial Activity

    Article • Antimicrobial Agents and Chemotherapy, November 2014, ASM Journals

    Dr Jasper Dingemanse

  10. Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects

    Article • British Journal of Clinical Pharmacology, October 2014, Wiley

    Dr Jasper Dingemanse

  11. Macitentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, does not affect cardiac repolarization in healthy subjects

    Article • Pulmonary Pharmacology & Therapeutics, October 2014, Elsevier

    Dr Jasper Dingemanse

  12. Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine

    Article • European Neuropsychopharmacology, August 2014, Elsevier

    Dr Jasper Dingemanse

  13. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics

    Article • Clinical & Experimental Allergy, July 2014, Wiley

    Dr Jasper Dingemanse

  14. Pharmacokinetic–Pharmacodynamic Relationships of Macitentan, a New Endothelin Receptor Antagonist, After Multiple Dosing in Healthy Korean Subjects

    Article • American Journal of Cardiovascular Drugs, June 2014, Springer Science + Business Media

    Dr Jasper Dingemanse

  15. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator

    Article • Journal of Pharmacokinetics and Pharmacodynamics, June 2014, Springer Science + Business Media

    Dr Jasper Dingemanse

  16. Investigation of the Effect of Macitentan on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Male Subjects

    Article • Clinical Drug Investigation, May 2014, Springer Science + Business Media

    Dr Jasper Dingemanse

  17. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects

    Article • Fundamental and Clinical Pharmacology, May 2014, Wiley

    Dr Jasper Dingemanse

  18. Pharmacokinetic Interactions Between the Orexin Receptor Antagonist Almorexant and the CYP3A4 Inhibitors Ketoconazole and Diltiazem

    Article • Journal of Pharmaceutical Sciences, May 2014, Elsevier

    Dr Jasper Dingemanse

  19. Reply to Letter: Age and Sex Effects on the Single- and Multiple-Dose Safety and Pharmacokinetics of the New Renin Inhibitor ACT-178882

    Article • Cardiovascular Therapeutics, April 2014, Wiley

    Dr Jasper Dingemanse

  20. Entry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexant

    Article • The Journal of Clinical Pharmacology, April 2014, Wiley

    Dr Jasper Dingemanse

  21. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882

    Article • European Journal of Clinical Pharmacology, April 2014, Springer Science + Business Media

    Dr Jasper Dingemanse

  22. Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies

    Article • Drug Design Development and Therapy, April 2014, Taylor & Francis

    Dr Jasper Dingemanse

  23. Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users

    Article • CNS Drugs, March 2014, Springer Science + Business Media

    Dr Jasper Dingemanse

  24. Validation of an LC-MS/MS method for the quantitative determination of the orexin receptor antagonist almorexant and its four primary metabolites in human plasma

    Article • Journal of Chromatography B, March 2014, Elsevier

    Dr Jasper Dingemanse

  25. Tolerability and Pharmacokinetics of ACT-280778, a Novel Nondihydropyridine Dual L/T-type Calcium Channel Blocker

    Article • Journal of Cardiovascular Pharmacology, February 2014, Wolters Kluwer Health

    Dr Jasper Dingemanse

  26. Challenges in collecting pharmacokinetic and pharmacodynamic information in an intensive care setting: PK/PD modelling of clazosentan in patients with aneurysmal subarachnoid haemorrhage

    Article • European Journal of Clinical Pharmacology, January 2014, Springer Science + Business Media

    Dr Jasper Dingemanse

  27. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1receptor modulator: Favorable impact of dose up-titration

    Article • The Journal of Clinical Pharmacology, January 2014, Wiley

    Dr Jasper Dingemanse

  28. Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive

    Article • European Journal of Clinical Pharmacology, December 2013, Springer Science + Business Media

    Dr Jasper Dingemanse

  29. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension

    Article • Expert Opinion on Drug Safety, November 2013, Informa Healthcare

    Dr Jasper Dingemanse

  30. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1receptor modulator, in the first-in-human study

    Article • British Journal of Clinical Pharmacology, November 2013, Wiley

    Dr Jasper Dingemanse

  31. Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans

    Article • Drugs in R&D, November 2013, Springer Science + Business Media

    Dr Jasper Dingemanse

  32. Setipiprant, a Selective Oral Antagonist of Human CRTH2: Relative Bioavailability of a Capsule and a Tablet Formulation in Healthy Female and Male Subjects

    Article • Clinical Therapeutics, November 2013, Elsevier

    Dr Jasper Dingemanse

  33. Pharmacokinetics of the novel dual endothelin receptor antagonist macitentan in subjects with hepatic or renal impairment

    Article • The Journal of Clinical Pharmacology, October 2013, Wiley

    Dr Jasper Dingemanse

  34. Age and Sex Effects on the Single- and Multiple-Dose Safety and Pharmacokinetics of the New Renin Inhibitor ACT-178882

    Article • Cardiovascular Therapeutics, September 2013, Wiley

    Dr Jasper Dingemanse

  35. Population Pharmacodynamic Modeling of Hyperglycemic Clamp and Meal Tolerance Tests in Patients with Type 2 Diabetes Mellitus

    Article • The AAPS Journal, August 2013, American Association of Pharmaceutical Scientists (AAPS)

    Dr Jasper Dingemanse

  36. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects

    Article • The Journal of Clinical Pharmacology, August 2013, Wiley

    Dr Jasper Dingemanse

  37. Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist

    Article • European Journal of Pharmaceutical Sciences, August 2013, Elsevier

    Dr Jasper Dingemanse

  38. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation

    Article • International Journal of Clinical Pharmacology and Therapeutics, June 2013, Dustri-Verlgag Dr. Karl Feistle

    Dr Jasper Dingemanse

  39. Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects

    Article • Drugs in R&D, June 2013, Springer Science + Business Media

    Dr Jasper Dingemanse

  40. Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose Almorexant, an Orexin Receptor Antagonist, in Healthy Elderly Subjects

    Article • Journal of Clinical Psychopharmacology, June 2013, Wolters Kluwer Health

    Dr Jasper Dingemanse

  41. Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

    Article • Clinical Pharmacokinetics, April 2013, Springer Science + Business Media

    Dr Jasper Dingemanse

  42. Comparative Pharmacokinetic, Pharmacodynamic, Safety, and Tolerability Profiles of 3 Different Formulations of Epoprostenol Sodium for Injection in Healthy Men

    Article • Clinical Therapeutics, April 2013, Elsevier

    Dr Jasper Dingemanse

  43. Effect of Multiple-Dose Diltiazem on the Pharmacokinetics of the Renin Inhibitor ACT-077825

    Article • Clinical Pharmacology in Drug Development, March 2013, Wiley

    Dr Jasper Dingemanse

  44. Drug-Drug Interaction Study of ACT-178882, a New Renin Inhibitor, and Diltiazem in Healthy Subjects

    Article • Clinical Drug Investigation, February 2013, Springer Science + Business Media

    Dr Jasper Dingemanse

  45. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans

    Article • European Neuropsychopharmacology, February 2013, Elsevier

    Dr Jasper Dingemanse

  46. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin

    Article • European Journal of Clinical Pharmacology, January 2013, Springer Science + Business Media

    Dr Jasper Dingemanse

  47. Miglustat effects on the basal nasal potential differences in cystic fibrosis

    Article • Journal of Cystic Fibrosis, January 2013, Elsevier

    Dr Jasper Dingemanse

  48. Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex

    Article • Pharmacology, January 2013, Karger Publishers

    Dr Jasper Dingemanse

  49. Pharmacokinetics, Pharmacodynamics, and Tolerability of ACT-077825, a New Direct Renin Inhibitor After Multiple-ascending Doses in Healthy Subjects

    Article • Journal of Cardiovascular Pharmacology, January 2013, Wolters Kluwer Health

    Dr Jasper Dingemanse

  50. Integrated pharmacokinetics and pharmacodynamics of epoprostenol in healthy subjects

    Article • British Journal of Clinical Pharmacology, November 2012, Wiley

    Dr Jasper Dingemanse

  51. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment

    Article • CHEST Journal, October 2012, Elsevier

    Dr Jasper Dingemanse

  52. Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Dual Endothelin Receptor Antagonist, in Subjects With Severe Renal Function Impairment

    Article • CHEST Journal, October 2012, Elsevier

    Dr Jasper Dingemanse

  53. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects

    Article • European Journal of Clinical Pharmacology, September 2012, Springer Science + Business Media

    Dr Jasper Dingemanse

  54. Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam

    Article • Fundamental and Clinical Pharmacology, July 2012, Wiley

    Dr Jasper Dingemanse

  55. Determination of 6-keto prostaglandin F1α and its metabolites in human plasma by LC–MS/MS

    Article • Journal of Chromatography B, July 2012, Elsevier

    Dr Jasper Dingemanse

  56. Comparable Pharmacokinetics And Pharmacodynamics Of Three Formulations Of Intravenous Epoprostenol Sodium

    Article • May 2012, American Thoracic Society

    Dr Jasper Dingemanse

  57. A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference

    Article • Journal of Cystic Fibrosis, May 2012, Elsevier

    Dr Jasper Dingemanse

  58. Lack Of Clinically Relevant Pharmacokinetic Interactions Between The Dual Endothelin Receptor Antagonist Macitentan And Sildenafil In Healthy Subjects

    Article • May 2012, American Thoracic Society

    Dr Jasper Dingemanse

  59. Effect Of Multiple-Dose Setipiprant, A Selective Oral CRTH2 Antagonist, On Allergen-Induced Airway Responses In Allergic Asthmatic Patients

    Article • May 2012, American Thoracic Society

    Dr Jasper Dingemanse

  60. Miglustat Improves Purkinje Cell Survival and Alters Microglial Phenotype in Feline Niemann-Pick Disease Type C

    Article • Journal of Neuropathology & Experimental Neurology, May 2012, Oxford University Press (OUP)

    Dr Jasper Dingemanse

  61. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

    Article • Xenobiotica, March 2012, Taylor & Francis

    Dr Jasper Dingemanse

  62. Entry-into-humans study with a new direct renin inhibitor

    Article • European Journal of Clinical Pharmacology, March 2012, Springer Science + Business Media

    Dr Jasper Dingemanse

  63. Validated LC–MS/MS method for the quantitative determination of the glucosylceramide synthase inhibitor miglustat in mouse plasma and human plasma and its application to a pharmacokinetic study

    Article • Journal of Pharmaceutical and Biomedical Analysis, February 2012, Elsevier

    Dr Jasper Dingemanse

  64. Development and validation of a fully automated online human dried blood spot analysis of bosentan and its metabolites using the Sample Card And Prep DBS System

    Article • Journal of Chromatography B, February 2012, Elsevier

    Dr Jasper Dingemanse

  65. Absolute Oral Bioavailability of Almorexant, a Dual Orexin Receptor Antagonist, in Healthy Human Subjects

    Article • Pharmacology, January 2012, Karger Publishers

    Dr Jasper Dingemanse

  66. Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

    Article • The AAPS Journal, December 2011, American Association of Pharmaceutical Scientists (AAPS)

    Dr Jasper Dingemanse

  67. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis

    Article • European Journal of Clinical Pharmacology, November 2011, Springer Science + Business Media

    Dr Jasper Dingemanse

  68. Food Effect and Biocomparison of Two Formulations of the Dual Orexin Receptor Antagonist Almorexant in Healthy Male Subjects

    Article • The Journal of Clinical Pharmacology, July 2011, Wiley

    Dr Jasper Dingemanse

  69. Macitentan: entry-into-humans study with a new endothelin receptor antagonist

    Article • European Journal of Clinical Pharmacology, May 2011, Springer Science + Business Media

    Dr Jasper Dingemanse

  70. Epoprostenol With Expanded Stability Has The Same Pharmacokinetic And Pharmacodynamic Profiles As Epoprostenol In Healthy Subjects

    Article • May 2011, American Thoracic Society

    Dr Jasper Dingemanse

  71. Influence of Severe Renal Impairment on the Pharmacokinetics of Clazosentan

    Article • The Journal of Clinical Pharmacology, March 2011, Wiley

    Dr Jasper Dingemanse

  72. Pharmacokinetics and Tolerability of Almorexant in Japanese and Caucasian Healthy Male Subjects

    Article • Pharmacology, January 2011, Karger Publishers

    Dr Jasper Dingemanse

  73. Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan

    Article • British Journal of Clinical Pharmacology, December 2010, Wiley

    Dr Jasper Dingemanse

  74. Drug Development for Pediatric Populations: Regulatory Aspects

    Article • Pharmaceutics, November 2010, MDPI AG

    Dr Jasper Dingemanse

  75. Phospholipidosis in healthy subjects participating in clinical studies: Ultrastructural findings in white blood cells

    Article • Experimental and Toxicologic Pathology, September 2010, Elsevier

    Dr Jasper Dingemanse

  76. Lack of a Pharmacokinetic Interaction Between Oral Treprostinil and Bosentan in Healthy Adult Volunteers

    Article • The Journal of Clinical Pharmacology, July 2010, Wiley

    Dr Jasper Dingemanse

  77. First-Phase Insulin Secretion Has Limited Impact on Postprandial Glycemia in Subjects with Type 2 Diabetes: Correlations Between Hyperglycemic Glucose Clamp and Meal Test

    Article • Diabetes Technology & Therapeutics, February 2010, Mary Ann Liebert Inc

    Dr Jasper Dingemanse

  78. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants

    Article • Antiviral Therapy, January 2010, International Medical Press

    Dr Jasper Dingemanse

  79. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study

    Article • British Journal of Clinical Pharmacology, December 2009, Wiley

    Dr Jasper Dingemanse, Professor Damien Bonnet

  80. Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan

    Article • European Journal of Pharmaceutical Sciences, November 2009, Elsevier

    Dr Jasper Dingemanse

  81. Acute Hemodynamic Effects of Single-Dose Sildenafil When Added to Established Bosentan Therapy in Patients With Pulmonary Arterial Hypertension: Results of the COMPASS-1 Study

    Article • The Journal of Clinical Pharmacology, November 2009, Wiley

    Dr Jasper Dingemanse

  82. Pharmacokinetics and Pharmacodynamics of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects

    Article • The Journal of Clinical Pharmacology, October 2009, Wiley

    Dr Jasper Dingemanse

  83. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus

    Article • British Journal of Clinical Pharmacology, October 2009, Wiley

    Dr Jasper Dingemanse

  84. Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis

    Article • Molecular Genetics and Metabolism, August 2009, Elsevier

    Dr Jasper Dingemanse

  85. Influence of Liver Cirrhosis on the Pharmacokinetics, Pharmacodynamics, and Safety of Tezosentan

    Article • The Journal of Clinical Pharmacology, April 2009, Wiley

    Dr Jasper Dingemanse

  86. Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects

    Article • The Journal of Clinical Pharmacology, May 2008, Wiley

    Dr Jasper Dingemanse

  87. Pharmacokinetic and pharmacodynamic aspects of the interaction between clazosentan and nimodipine in healthy subjects

    Article • January 2008, Springer Science + Business Media

    Dr Jasper Dingemanse

  88. A pharmacokinetic study of clazosentan in patients with aneurysmal subarachnoid haemorrhage

    Article • January 2008, Springer Science + Business Media

    Dr Jasper Dingemanse

  89. Pseudohallucinations After Zolpidem Intake

    Article • Journal of Clinical Psychopharmacology, December 2007, Wolters Kluwer Health

    Dr Jasper Dingemanse

  90. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

    Article • European Journal of Clinical Pharmacology, November 2007, Springer Science + Business Media

    Dr Jasper Dingemanse

  91. Influence of Ethnic Origin and Sex on the Pharmacokinetics of Clazosentan

    Article • The Journal of Clinical Pharmacology, November 2007, Wiley

    Dr Jasper Dingemanse

  92. Influence of Food Intake on the Pharmacokinetics of Miglustat, an Inhibitor of Glucosylceramide Synthase

    Article • The Journal of Clinical Pharmacology, October 2007, Wiley

    Dr Jasper Dingemanse

  93. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome

    Article • Hepatology, September 2007, Wiley

    Dr Jasper Dingemanse, Professor Rajiv Jalan

  94. Reply to 'Promotion of sleep by targeting the orexin system in rats, dogs and humans'

    Article • Nature Medicine, May 2007, Springer Science + Business Media

    Dr Jasper Dingemanse

  95. Promotion of sleep by targeting the orexin system in rats, dogs and humans

    Article • Nature Medicine, January 2007, Springer Science + Business Media

    Dr Jasper Dingemanse

  96. Integrated??Pharmacokinetics??and Pharmacodynamics in??Drug??Development

    Article • Clinical Pharmacokinetics, January 2007, Springer Science + Business Media

    Dr Jasper Dingemanse

  97. Effect of Gender on the Tolerability, Safety and Pharmacokinetics of Clazosentan Following Long-Term Infusion

    Article • Clinical Drug Investigation, January 2007, Springer Science + Business Media

    Dr Jasper Dingemanse

  98. PHARMACOKINETIC INTERACTION BETWEEN TADALAFIL AND BOSENTAN IN HEALTHY MALE SUBJECTS

    Article • CHEST Journal, October 2006, Elsevier

    Dr Jasper Dingemanse

  99. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist

    Article • European Journal of Clinical Pharmacology, April 2006, Springer Science + Business Media

    Dr Jasper Dingemanse

  100. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects

    Article • British Journal of Clinical Pharmacology, February 2006, Wiley

    Dr Jasper Dingemanse

  101. Comparative Investigation of the Pharmacokinetics of Bosentan in Caucasian and Japanese Healthy Subjects

    Article • The Journal of Clinical Pharmacology, January 2005, Wiley

    Dr Jasper Dingemanse

  102. Effects of the Endothelin Receptor Antagonist Bosentan on Hemodynamics, Symptoms and Functional Capacity in Japanese Patients With Severe Pulmonary Hypertension

    Article • Circulation Journal, January 2005, Japanese Circulation Society

    Dr Jasper Dingemanse

  103. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure

    Article • European Journal of Heart Failure, August 2004, Wiley

    Dr Jasper Dingemanse

  104. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD

    Article • American Journal of Kidney Diseases, May 2004, Elsevier

    Dr Jasper Dingemanse

  105. Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist

    Article • Clinical Pharmacokinetics, January 2004, Springer Science + Business Media

    Dr Jasper Dingemanse

  106. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile

    Article • British Journal of Clinical Pharmacology, October 2003, Wiley

    Dr Jasper Dingemanse

  107. Low dose tezosentan, an intravenous dual endothelin receptor antagonist, decreases type B-natruretic peptide levels in patients with acute decompensated heart failure

    Article • Journal of Cardiac Failure, October 2003, Elsevier

    Dr Jasper Dingemanse

  108. Determination of tezosentan, a parenteral endothelin receptor antagonist, in human plasma by liquid chromatography–tandem mass spectrometry

    Article • Journal of Chromatography B, July 2003, Elsevier

    Dr Jasper Dingemanse

  109. Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjects

    Article • European Journal of Drug Metabolism and Pharmacokinetics, March 2003, Springer Science + Business Media

    Dr Jasper Dingemanse

  110. Investigation of the Mutual Pharmacokinetic Interactions Between Bosentan, a Dual Endothelin Receptor Antagonist, and Simvastatin

    Article • Clinical Pharmacokinetics, January 2003, Springer Science + Business Media

    Dr Jasper Dingemanse

  111. Influence of Mild Liver Impairment on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist

    Article • The Journal of Clinical Pharmacology, January 2003, Wiley

    Dr Jasper Dingemanse

  112. Psychomotor and Anxiolytic Effects????????? of Mexazolam in Patients with Generalised Anxiety Disorder

    Article • Clinical Drug Investigation, January 2003, Springer Science + Business Media

    Dr Jasper Dingemanse

  113. Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor

    Article • European Journal of Pharmacology, August 2002, Elsevier

    Dr Jasper Dingemanse

  114. Entry-Into-Humans Study with Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist

    Article • Journal of Cardiovascular Pharmacology, June 2002, Wolters Kluwer Health

    Dr Jasper Dingemanse

  115. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

    Article • British Journal of Clinical Pharmacology, June 2002, Wiley

    Dr Jasper Dingemanse

  116. Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist

    Article • European Journal of Clinical Pharmacology, May 2002, Springer Science + Business Media

    Dr Jasper Dingemanse

  117. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin

    Article • British Journal of Clinical Pharmacology, May 2002, Wiley

    Dr Jasper Dingemanse

  118. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects

    Article • British Journal of Clinical Pharmacology, April 2002, Wiley

    Dr Jasper Dingemanse

  119. Influence of Food Intake and Formulation on the Pharmacokinetics and Metabolism of Bosentan, a Dual Endothelin Receptor Antagonist

    Article • The Journal of Clinical Pharmacology, March 2002, Wiley

    Dr Jasper Dingemanse

  120. Multiple-dose Tolerability, Pharmacodynamics, and Pharmacokinetics of the Quinolizinone Hypnotic Ro 41???3696 in Elderly Subjects

    Article • Clinical Neuropharmacology, March 2001, Wolters Kluwer Health

    Dr Jasper Dingemanse

  121. Investigation of a correlation between monoamine oxidase B and catechol-O-methyltransferase activity in human blood cells

    Article • European Journal of Pharmaceutical Sciences, December 2000, Elsevier

    Dr Jasper Dingemanse

  122. Pharmacokinetics and Pharmacodynamics of the Acetylcholinesterase Inhibitor Metrifonate in Patients With Renal Impairment

    Article • Therapeutic Drug Monitoring, June 1999, Wolters Kluwer Health

    Dr Jasper Dingemanse

  123. Pharmacokinetic-Pharmacodynamic Investigation of a Possible Interaction Between Steady-State Temocapril and Warfarin in Healthy Subjects

    Article • Clinical Drug Investigation, January 1999, Springer Science + Business Media

    Dr Jasper Dingemanse

  124. Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the “serotonin syndrome”*

    Article • Clinical Pharmacology & Therapeutics, April 1998, Springer Science + Business Media

    Dr Jasper Dingemanse

  125. Inhibition of dextromethorphan metabolism by moclobemide

    Article • Psychopharmacology, January 1998, Springer Science + Business Media

    Dr Jasper Dingemanse

  126. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Article • Drug Development Research, September 1997, Wiley

    Dr Jasper Dingemanse

  127. Pharmacodynamics of benserazide assessed by its effects on endogenous and exogenous levodopa pharmacokinetics*

    Article • British Journal of Clinical Pharmacology, July 1997, Wiley

    Dr Jasper Dingemanse

  128. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-6 inhibitor lazabemide in healthy subjects

    Article • British Journal of Clinical Pharmacology, January 1997, Wiley

    Dr Jasper Dingemanse

  129. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-6 inhibitor lazabemide in healthy subjects

    Article • British Journal of Clinical Pharmacology, January 1997, Wiley

    Dr Jasper Dingemanse

  130. Modification of the Cardiovascular Effects of Ephedrine by the Reversible Monoamine Oxidase A-Inhibitor Moclobemide

    Article • Journal of Cardiovascular Pharmacology, December 1996, Wolters Kluwer Health

    Dr Jasper Dingemanse

  131. Pharmacokinetic-Pharmacodynamic Interactions Between Two Selective Monoamine Oxidase Inhibitors: Moclobemide and Selegiline

    Article • Clinical Neuropharmacology, October 1996, Wolters Kluwer Health

    Dr Jasper Dingemanse

  132. The role of cytochrome P450 2D6 in the metabolism of moclobemide

    Article • European Neuropsychopharmacology, August 1996, Elsevier

    Dr Jasper Dingemanse

  133. Determination of 3,4-Dihydroxyphenylacetic Acid and 5-Hydroxyindoleacetic Acid in Human Plasma by a Simple and Rapid High-performance Liquid Chromatography Assay*

    Article • Journal of Pharmaceutical Sciences, April 1996, American Geophysical Union (AGU)

    Dr Jasper Dingemanse

  134. Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans

    Article • Biomedical Chromatography, January 1996, Wiley

    Dr Jasper Dingemanse

  135. Pharmacokinetics and Pharmacodynamics of Ro 41-3696, a Novel Nonbenzodiazepine Hypnotic

    Article • The Journal of Clinical Pharmacology, August 1995, Wiley

    Dr Jasper Dingemanse

  136. Pharmacotherapy of insomnia: Practice and prospects

    Article • May 1995, Springer Science + Business Media

    Dr Jasper Dingemanse

  137. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans*

    Article • Clinical Pharmacology & Therapeutics, May 1995, Springer Science + Business Media

    Dr Jasper Dingemanse

  138. Switch in Treatment From Tricyclic Antidepressants to Moclobemide

    Article • Journal of Clinical Psychopharmacology, February 1995, Wolters Kluwer Health

    Dr Jasper Dingemanse

  139. Pharmacological interactions with reversible MAOIs and clinical relevance

    Article • European Neuropsychopharmacology, September 1993, Elsevier

    Dr Jasper Dingemanse

  140. An update of recent moclobemide interaction data

    Article • International Clinical Psychopharmacology, January 1993, Wolters Kluwer Health

    Dr Jasper Dingemanse

  141. An update of recent moclobemide interaction data

    Article • International Clinical Psychopharmacology, January 1993, Wolters Kluwer Health

    Dr Jasper Dingemanse

  142. Influence of moclobemide on ibuprofen-induced faecal blood loss

    Article • Psychopharmacology, February 1992, Springer Science + Business Media

    Dr Jasper Dingemanse

  143. The influence of dosage time of midazolam on its pharmacokinetics and effects in humans

    Article • Clinical Pharmacology & Therapeutics, July 1991, Springer Science + Business Media

    Dr Jasper Dingemanse

  144. Pharmacodynamics of Tolerance Development to the Anesthetic and Anticonvulsant Effects of Phenobarbital in Rats

    Article • Journal of Pharmaceutical Sciences, March 1990, Elsevier

    Dr Jasper Dingemanse

  145. Phannacokinetic-pharmacodynamic modelling of the anticonvulsant effect of oxazepam in individual rats

    Article • Bone Marrow Transplantation, January 1990, Wiley

    Dr Jasper Dingemanse

  146. Diazepam reverses the effects of pentylenetetrazole in rat pups by acting at type 2 benzodiazepine receptors

    Article • Pharmacology Biochemistry and Behavior, March 1989, Elsevier

    Dr Jasper Dingemanse

  147. Determination of the threshold for convulsions by direct cortical stimulation

    Article • Epilepsy Research, March 1989, Elsevier

    Dr Jasper Dingemanse

  148. Strategy to Assess the Role of (Inter)active Metabolites in Pharmacodynamic Studies In-vivo: a Model Study with Heptabarbital

    Article • Journal of Pharmacy and Pharmacology, August 1988, Oxford University Press (OUP)

    Dr Jasper Dingemanse

  149. Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure

    Article • Journal of Pharmacokinetics and Biopharmaceutics, April 1988, Springer Science + Business Media

    Dr Jasper Dingemanse

  150. Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: An overview

    Article • Pharmacology & Therapeutics, January 1988, Elsevier

    Dr Jasper Dingemanse

  151. Determination of Benzodiazepines: The Present-Day Scene

    Article • January 1986, Springer Science + Business Media

    Dr Jasper Dingemanse